Endocrine Abstracts

Background: The NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional study (2006–2016), assessed the effectiveness and safety of real-life treatment with Norditropin®. Out of 20,548 enrolled patients, 20,195 (paediatric/adult; 17,711/2484) were included in the full analysis set (FAS) and 12,938 (11,967/971) in the effectiveness analysis set (EAS). Outcomes were assessed in children with growth hormone deficiency (...

Objectives: Congenital heart disease, especially pulmonary stenosis, is a frequent comorbidity in patients with Noonan syndrome (NS). Patients with NS are also at increased risk of childhood leukaemia and solid tumours. Among solid tumours, brain tumours, including glioneuronal tumours, have been described in younger patients but remain rare. Current safety data do not indicate an association of growth hormone (GH) therapy with increased risk for development or progression of ...

Introduction: Patients with AGHD receiving GH often have comorbidities requiring concomitant treatment. We evaluated patterns of concomitant medication use relative to GH therapy initiation in patients with AGHD.Methods: Patients with AGHD with data on concomitant medications enrolled in NordiNet® IOS (NCT00960128), an international, non-interventional study, receiving GH (Norditropin®, Novo Nordisk A/S, Denmark) therapy w...

Introduction: The clinical significance of the impact of GH on glucose homeostasis in adults with GH deficiency (GHD) remains unclear. We report the impact of 4 years of continuous GH therapy on HbA1c and progression to diabetes.Methods: Data were analysed from patients with adult-onset GHD (>20 years old) enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), an observational study, and treated with GH (Norditropin<su...